Table 3.

Mutation profile of the organoid lines in comparison with reference cohorts for non-muscle invasive bladder cancer (NMIBC) [48] and muscle-invasive bladder cancer (MIBC) [49] extracted from the cBioPortal [50,51].

	TCGA		Pauli2017	Lee2018		Yu2021	Cai2021
Mutations	NMIB	MIB	Tumor	NMIB	MIB	MIB	MIB
TP53	21%	48%	33% (1/3)	31% (5/16)	50% (3/6)	33% (1/3)	100% (1/1)
KMT2D	24%	28%	33% (1/3)	38% (6/16)	33% (2/6)	-	100% (1/1)
KDM6A	48%	26%	-	63% (10/16)	50% (3/6)	-	-
ARID1A	29%	25%	-	19% (3/16)	50% (3/6)	33% (1/3)	-
PIK3CA	28%	22%	33% (1/3)	31% (5/16)	33% (2/6)	-	-
KMT2C	11%	19%	-	44% (7/16)	33% (2/6)	33% (1/3)	-
RB1	4%	18%	33% (1/3)	6% (1/16)	0% (0/6)	33% (1/3)	-
EP300	14%	15%	-	6% (1/16)	33% (2/6)	33% (1/3)	100% (1/1)
FGFR3	45%	14%	33% (1/3)	56% (9/16)	50% (3/6)	-	-
STAG2	21%	14%	-	19% (3/16)	17% (1/6)	-	-
FAT1	26%	12%	-	-	-	33% (1/3)	100% (1/1)
CREBBP	21%	12%	33% (1/3)	19% (3/16)	33% (2/6)	33% (1/3)
ERBB2	18%	12%	-	13% (2/16)	0% (0/6)	33% (1/3)	100% (1/1)
KMT2A	9%	11%	33% (1/3)	-	-	-	-
ERBB3	11%	10%	-	13% (2/16)	0% (0/6)	-	-
CDKN1A	11%	9%	-	0% (0/16)	17% (1/6)	33% (1/3)	-
FBXW7	14%	8%	-	6% (1/16)	33% (2/6)	-	-
TSC1	11%	8%	-	31% (5/16)	17% (1/6)	-	-
NFE2L2	6%	6%	-	0% (0/16)	17% (1/6)	-	-
RXRA	na	6%	33% (1/3)	-	-	-	-
RHOB	na	6%	33% (1/3)	-	-	-	-
CTNNB1	9%	3%	-	25% (4/16)	17% (1/6)	-	-
FOXA1	6%	3%	-	0% (0/16)	17% (1/6)	-	-
Deletions/amplifications
CDKN2A	16%	33%	33% (1/3)	75% (12/16)	33% (2/6)	-	-
E2F3	3%	16%	33% (1/3)	19% (3/16)	33% (2/6)	-	-
CCND1	7%	12%	-	0% (0/16)	17% (1/6)	-	-
CCNE1	na	11%	-	13% (2/16)	0% (0/6)	-	-
MDM2	7%	9%	33% (1/3)	6% (1/16)	0% (0/6)	-	-
PTEN	na	5%	33% (1/3)	6% (1/16)	0% (0/6)	-	-
EGFR	na	5%	-	6% (1/16)	0% (0/6)	-	-